Aduro BioTech, Inc. (ADRO)
ADRO Price and Sentiment
ADRO Latest news
Aduro Biotech (KDNY) Upgraded to Buy: What Does It Mean for the Stock?
2020-12-01 12:00Aduro Biotech (KDNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aduro Biotech (KDNY) Reports Q3 Loss, Tops Revenue Estimates
2020-11-05 20:20Aduro Biotech (KDNY) delivered earnings and revenue surprises of -291.30% and 37.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech (KDNY) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2020-10-29 12:35Aduro Biotech (KDNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aduro Biotech (KDNY) Upgraded to Buy: Here's What You Should Know
2020-10-16 12:00Aduro Biotech (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Momentum Investors Will Love Aduro Biotech (KDNY)
2020-10-13 12:00Does Aduro Biotech (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
2020-10-05 09:00Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
2020-10-01 16:05One-for-Five Reverse Stock Split to be Effective October 2, 2020
Chinook Therapeutics raises $106M as it prepares to merge with Aduro Biotech
2020-08-19 10:32Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech.
Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates
2020-08-03 19:15Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2020-07-30 12:33Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.